

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



ENGRAILED 2 (EN2) Genetic and Functional Analysis

Jiyeon Choi¹, Silky Kamdar¹, Taslima Rahman¹,
Paul G Matteson¹ and James H Millonig^{1,2,3}

¹Center for Advanced Biotechnology and Medicine,

²Department of Neuroscience and Cell Biology,
UMDNJ-Robert Wood Johnson Medical School,

³Department of Genetics, Rutgers University, Piscataway NJ,
USA

1. Introduction

Our autism research has focused on the homeobox transcription factor, *ENGRAILED 2* (*EN2*). Prior to the advent of genome wide association and re-sequencing analysis, we selected *EN2* as a candidate gene due to neuroanatomical similarities observed between individuals with autism and mouse *En2* mutants.

Animal studies have demonstrated that *En2* is expressed throughout CNS development and regulates numerous cell biological processes implicated in ASD including connectivity, excitatory/inhibitory (E/I) circuit balance, and neurotransmitter development. The relevance of these functions to ASD etiology is discussed.

Human genetic analysis by us determined that two intronic SNPs, *rs1861972* and *rs1861973*, are significantly associated with Autism Spectrum Disorder (ASD). We observed the common haplotype (*rs1861972-rs1861973* A-C) is over-transmitted to affected individuals while the *rs1861972-rs1861973* G-T haplotype is over-represented in unaffected siblings. Significant results were observed in 3 datasets (518 families, 2336 individuals, $P=.00000035$). 6 other groups have also reported association of *EN2* with ASD, suggesting that *EN2* is an ASD susceptibility gene. These results are discussed.

However if *EN2* contributes to ASD risk, we would expect the ASD-associated A-C haplotype to segregate with a polymorphism that is functional and affects either the regulation or activity of *EN2*. Linkage disequilibrium mapping, re-sequencing and additional association analysis was performed, and identified the A-C haplotype as the best candidate for functional analysis. Luciferase assays conducted in primary mouse neuronal cultures demonstrated that the A-C haplotype functions as a transcriptional activator and specifically binds a protein complex. Transgenic mouse studies have demonstrated that the A-C haplotype is also functional, increasing gene expression *in vivo*. Finally, human post-mortem studies indicate *EN2* levels are also increased in individuals with autism. Thus, the ASD-associated A-C haplotype is functional and increased *EN2* levels are consistently correlated with ASD.

Six significant CpG islands also flank human *EN2*. Preliminary studies indicate hypomethylation of these CpGs can also result in increased *EN2* levels, suggesting

epigenetic alterations influenced by non-genetic environmental factors can affect *EN2* levels. To study how genetic and epigenetic changes may function together to influence *EN2* regulation and CNS development, we are creating a chromosomal engineered knock-in that will replace ~75kb of mouse *En2* with the human gene.

In summary *EN2* is consistently associated with ASD and functions in developmental pathways implicated in ASD. In addition, we have shown that the ASD-associated haplotype is functional, resulting in increased expression both in neuronal cultures *in vitro* and in transgenic mice *in vivo*. Increased levels are also observed in human post-mortem samples. Together these human genetic data along with our molecular, mouse and post-mortem studies indicate that *EN2* is an ASD susceptibility gene

2. Selection of *ENGRAILED 2* as a candidate gene

Before genome-wide strategies were available for identifying common and rare variants for ASD, my laboratory decided to test candidate genes based upon neuroanatomical phenotypes. When we started this work in 2003, two cerebellar neuroanatomical phenotypes were consistently observed in individuals with ASD: a decrease in cerebellar volume (hypoplasia) and fewer Purkinje neurons (Bauman and Kemper 1985; Bauman 1986; Courchesne, Yeung-Courchesne et al. 1988; Courchesne 1997; Amaral, Schumann et al. 2008). We knew of numerous mouse mutants that displayed similar morphological phenotypes so we decided to test these genes for association in the available Autism Genetic Resource Exchange (AGRE) dataset. A list of nearly 100 genes were compiled that displayed similar cerebellar phenotypes in the mouse and individuals with ASD. The list also included genes that at the time were expressed in the cerebellum in specific spatial-temporal patterns suggesting they were likely to contribute to development. These genes were then placed on the human genome to determine which ones mapped near polymorphic markers that displayed linkage to ASD.

Many of the genes mapped to possibly interesting locations so we prioritized our association analysis by the following criteria: i) distance to SSLP marker, ii) LOD score or statistical significance of marker, iii) whether segregation or linkage to the chromosomal region had been replicated in multiple studies, iv) whether the genomic region displayed linkage in the AGRE dataset which would be used for our association analysis, v) whether mouse mutants existed for the gene, vi) and the similarity between reported mouse and ASD cerebellar phenotypes

Based on these criteria we selected the homeobox transcription factor *ENGRAILED 2* (*EN2*) as a candidate gene. *EN2* belongs to a class of transcription factors that are homologous in their DNA binding domain called the homeobox. Homeobox transcription factors regulate gene expression by binding to AT-rich DNA elements, and play central roles in coordinating development. Many homeobox genes are evolutionarily conserved from *Drosophila* to humans. The *engrailed* gene was first identified in classical genetic screens for developmental regulators in *Drosophila*. Humans and mice have two *Engrailed* genes, *Engrailed 1* (*En1*) and *Engrailed 2* (*En2*). Both *En1* and *En2* regulate important aspects of CNS development (see Section 4 – *ENGRAILED 2* function)

Human *EN2* maps to distal chromosome 7 (7q36.3), near markers that display linkage to ASD in several datasets (Liu, Nyholt et al. 2001; Alarcon, Cantor et al. 2002; Auranen, Vanhala et al. 2002). Two of these studies had been performed using AGRE families. In addition two different *En2* mouse mutations existed – a traditional knock-out or deletion of

En2, and a transgenic misexpression mutant. In the knockout the cerebellum is reduced in size and cell counts have determined an ~30-40% reduction in all the major cerebellar cell types including Purkinje cells (Millen, Wurst et al. 1994; Kuemerle, Zanjani et al. 1997). In the transgenic *En2* is misexpressed in a subset of Purkinje cells and similar phenotypes were observed (40-50% reduction in cerebellar area; ~40% decrease in the number of adult Purkinje cells)(Baader, Sanlioglu et al. 1998).

Significant association of *EN2* with ASD was initially demonstrated by us and has now been reported by 5 additional groups (Brune, Korvatska et al. 2007; Wang, Jia et al. 2008; Yang, Lung et al. 2008; Sen, Singh et al. 2010; Yang, Shu et al. 2010). Prior to summarizing these data, we will first describe the known expression of mouse and human *EN2* as well as the cell biological processes regulated by *En2* in the developing and adult brain.

3. *Engrailed 2* expression during development

Mouse *En2* expression has been evaluated primarily by *in situ* hybridization and lacZ knock-in mice (see Table 1 for summary). In these studies *En2* expression is initiated at E8.0 at the junction between the midbrain and hindbrain. *En2* continues to be expressed in a majority of mid-hindbrain cells from E8.5 to E12.5. These *En2* expressing cells will generate the cerebellum and midbrain colliculi dorsally, as well as parts of the serotonin (raphe nucleus) and norepinephrine (locus coeruleus) neurotransmitter systems ventrally. By E17.5 *En2* expression becomes more spatially restricted. In the chick tectum *En2* is expressed in a rostral to caudal gradient, while in the cerebellum it is stripe-like. By post-natal day 6 *En2* transcripts are restricted to the differentiating cells in the external germinal layer and developing inner granule cell layer of the cerebellum. In the adult *En2* continues to be expressed in mature cerebellar granule cells. Finally, QRTPCR studies indicate *En2* is also expressed at low levels in adult hippocampus.

Developmental Stage	Expression	Function
E8.0-E12.5	Mid-hindbrain junction	A-P patterning, Neurotransmitter development
E12.5-E15.5	Developing cerebellum, colliculi, ventral mid- hindbrain nuclei including LC and RN, periaqueductal gray	Retinal-tectal mapping, Neurotransmitter development
E15.5-P0	Developing cerebellum, colliculi,	Retinal-tectal mapping, cerebellar connectivity
P0-P12	Cerebellum (differentiating Granule cells)	Cell cycle and differentiation
Adult	Mature granule cells	Unknown

Table 1. Summary of *En2* expression and function from animal studies

A limited number of human *ENGRAILED 2* expression studies have been performed. One analysis conducted on 18-21 weeks post-conception fetuses demonstrated widespread expression for both *ENGRAILED 1* and *2* genes throughout the mid-hindbrain region including the cerebellar cortex and deep nuclei. Expression was also observed in several ventral hindbrain nuclei (inferior olive, arcuate nucleus, caudal raphe nucleus)(Zec, Rowitch

et al. 1997). Western blot analysis conducted on cerebellar samples at later gestational ages (40 weeks) indicated abundant expression for both EN proteins (Logan, Hanks et al. 1992). Interestingly, recent microarray analysis performed by The Allen Institute for Brain Science demonstrates abundant expression throughout the cerebellum (cortex and deep nuclei) but also in numerous forebrain and midbrain structures (basal ganglia, amygdala, thalamus)(Figure 1). A complete developmental analysis of human *EN2* expression has not been reported. These data suggest human adult brain *EN2* expression is more widespread than mouse *En2*, and in fore- and mid-brain structures relevant to ASD phenotypes.




Fig. 1. Human *EN2* expression. Microarray data of microdissected brain regions performed by The Allen Institute for Brain Science indicate that *EN2* is expressed in the basal ganglia (purple), amygdala (pink), thalamus (green) as well as cerebellum and brainstem (blue). A) sagittal, B) horizontal, and C) caudal views

4. *ENGRAILED 2* function

Molecular studies have determined that *En2* functions as a transcriptional repressor. The protein regulates numerous cell biological pathways during CNS development but has a well-characterized function in establishing connectivity maps. Emerging data also supports *En2* function in E/I circuit balance as well as serotonin and norepinephrine neurotransmitter development. All of these cellular processes have been implicated in ASD etiology.

4.1 Transcriptional repressor function of *En2*

Molecular studies indicate the *Engrailed 2* protein primarily functions as a transcriptional repressor, which is mediated by several different protein domains (Figure 2). DNA binding occurs through the homeodomain to a generic AT rich cis-sequence recognized by homeobox transcription factors. Two domains (*engrailed* homology region 1 (EH1) and EH5) contribute to *Engrailed* repressor activity. EH1 is located in the N-terminal portion of the protein while the EH5 domain is immediately 3' of the homeodomain in the C terminal portion of the protein. Both domains bind the co-repressor Groucho, while EH1 is sufficient to confer repression activity when transferred to a transcriptional activator. *Engrailed* repressor function is mediated by two different mechanisms. The protein can actively block the trans-activation of activators by binding to nearby cis-sequences. Alternatively, the *engrailed* proteins compete for the binding of the basal transcriptional machinery to TATA box sequences (Ohkuma, Horikoshi et al. 1990; Jaynes and O'Farrell 1991; Tolkunova,

Fujioka et al. 1998). Finally, two other domains (EH2 and EH3) bind the Pbx family of homeodomain transcription factors, which affect DNA binding specificity (van Dijk and Murre 1994; Peltenburg and Murre 1997).




Fig. 2. En protein domains. The En protein structure is illustrated and the different En interaction domains are demarcated in following colors: translation initiation factor eIF4E binding site, transcriptional repressor domains, PBX interactions domains, homeodomain, and penetratin domain. EH1-5 indicate engrailed homology domains 1 through 5.

4.2 En2 regulates mid-hindbrain patterning

Mouse and chick studies have determined that En2 coordinates multiple cell biological process throughout development. From E8.0-E12.5, *En2* and *En1* are spatially overlapping at the mid-hindbrain junction and both genes function to restrict progenitors to a midbrain and hindbrain lineage (Joyner 1996). *En2* temporal expression commences a few hours after *En1* transcripts are first detected and because of this difference, the *En1* knock-out mouse displays a more severe phenotype with a deletion of mid-hindbrain structures (Wurst, Auerbach et al. 1994). Knock-in experiments where *En2* is targeted to the *En1* locus are sufficient to rescue this phenotype, demonstrating that En2 is functionally redundant to En1 at this early stage of development (Hanks, Wurst et al. 1995).

4.3 Engrailed genes and 5HT and NE neurotransmitter system development

Previous studies have demonstrated that the *Engrailed* genes are important in the development and maintenance of substantia nigra neurons in the dopamine neurotransmitter system. These data are reviewed elsewhere (Simon, Saueressig et al. 2001; Alberi, Sgado et al. 2004; Simon, Thuret et al. 2004; Gherbassi and Simon 2006; Sgado, Alberi et al. 2006). Instead we focus on the role of the *En* genes on serotonin (5HT) and norepinephrine (NE) development, since abnormalities in these neurotransmitter systems have been more consistently implicated in ASD.

Mutations in the *Engrailed* genes affect the development of ventral mid-hindbrain nuclei that synthesize NE and 5HT: the locus coeruleus (LC) and raphe nuclei (RN) respectively. The LC is generated early in development (E9-E10 in the mouse) from the dorsal mid-hindbrain junction. The LC is deleted in the double *En1*^{-/-} *En2*^{-/-} knockout mice but appears relatively normal in the single knockouts suggesting the genes compensate for each other during development. The RN is generated in the ventral mid-hindbrain and express 5HT by E11.5. Several transcription factors including Pet1, Lmx1b and Gata3 are important in the generation of RN. Recent analysis indicates that both *En* genes are expressed in the progenitors of RN at E11.5 and to continue to be expressed in post-mitotic rostral 5HT neurons. In addition an ~50% loss of neurons is observed in the dorsal RN by E16.5 in the double *En* knockouts. Like the LC phenotype the RN is relatively normal in the single knockouts suggesting the genes compensate for each other during development (Simon, Saueressig et al. 2001; Simon, Scholz et al. 2005; Sgado, Alberi et al. 2006; Fox 2010). Neurochemical data from our collaborator, Emanuel DiCicco-Bloom MD, have

demonstrated abnormal levels of NE and 5HT in both the fore- and hindbrain structures of the *En2* knockout (Lin 2010). These data indicate that the development of the 5HT and NE neurotransmitter systems are regulated by the Engrailed proteins.

Numerous studies have implicated the 5HT and NE pathways in ASD. The 5HT pathway regulates mood, eating, body temperature and arousal, some of which are often perturbed in individuals with ASD. Abnormalities in the 5HT pathway have been consistently observed in individuals with ASD. Blood platelet hyperserotonemia has been reported since the 1960s in ~30% of affected individuals (Ritvo, Yuwiler et al. 1970; Campbell, Friedman et al. 1975; Takahashi, Kanai et al. 1976; Anderson 1987; Anderson, Freedman et al. 1987; McBride, Anderson et al. 1989; Cook, Rowlett et al. 1992; Lam, Aman et al. 2006). However, several studies suggest 5HT functioning is depressed in the CNS of individuals with autism. For example, serotonin reuptake inhibitors (SSRIs) can improve some of the symptoms of ASD (Cook, Rowlett et al. 1992; Gordon, State et al. 1993). In addition, the rate-limiting step of 5HT synthesis is the hydroxylation of tryptophan and acute depletion of tryptophan worsens ASD symptoms (McDougle, Naylor et al. 1996; McDougle, Naylor et al. 1996). The NE neurotransmitter system regulates attention, stress, anxiety, and memory, some of which are also affected in individuals with ASD. Unlike the 5HT system, the peripheral and central NE systems are tightly coordinated. Five studies have revealed increases in NE in the blood (Lake, Ziegler et al. 1977; Launay, Bursztejn et al. 1987; Leventhal, Cook et al. 1990; Leboyer, Bouvard et al. 1992; Minderaa, Anderson et al. 1994). However since plasma NE has a very short half-life, it remains possible that this increase is due to arousal at the time of blood drawing.

4.4 *En2* regulates connectivity

From E15.5-P0, *En2* is expressed in a stripe-like pattern in the cerebellum. *En2* is one of many patterning genes that are expressed in this stripe-like pattern at this age (*En1*, *Shh*, *Pax2* and *Wnt7b*) (Millen, Hui et al. 1995). Interestingly, these stripe-like expression domains are coincident with the innervation of cerebellar afferents (mossy and climbing fibers), suggesting that these patterning genes regulate the topographic mapping of axons. Consistent with this possibility, *En2* mouse mutants display connectivity phenotypes disrupting the innervation of mossy fibers (Herrup and Kuemerle 1997; Baader, Sanlioglu et al. 1998; Baader, Vogel et al. 1999; Sillitoe, Stephen et al. 2008; Sillitoe, Gopal et al. 2009; Sillitoe, Vogel et al. 2010). Thus *En2* is important in establishing the cerebellar connectivity map during development.

Several studies indicate the Engrailed proteins are secreted and function as axon guidance proteins for retinal-tectal mapping. Initial EM and protein studies from the Prochiantz group indicated that a subset of the Engrailed proteins are associated with caveolae-like vesicles (Joliot, Trembleau et al. 1997). Subsequent work demonstrated that ~5% of the Engrailed protein are secreted and they are internalized by neighboring cells. A protein sequence embedded in the homeodomain called the penetratin domain is responsible for this activity (Joliot, Maizel et al. 1998). In addition, *in vitro* cultures demonstrated that exogenous *En2* acts as a guidance cue for isolated retinal axons transected from the nucleus. Imaging studies indicate *En2* is endocytosed by these growth cones. The protein then interacts with the eukaryotic initiation factor 4E (eIF4E), and *En2* mutations that prevent eIF4E interaction fail to cause axon turning. *En2* also results in the phosphorylation of eIF4E and its binding protein, 4E-BP1, in axons, which is typically associated with translation initiation (Brunet, Weinel et al. 2005). Recent antibody experiments that block exogenous

activity cause significant connectivity defects in the tectum (Wizenmann, Brunet et al. 2009). Interestingly, several other developmentally important transcription factors (Pax6, Otx2) also display non-cell autonomous phenotypes (Lesaffre, Joliot et al. 2007; Sugiyama, Di Nardo et al. 2008), suggesting this phenomenon is not specific to the Engrailed genes.

Thus, a small proportion of the Engrailed 2 protein is secreted and is important in regulating connectivity through local translation. The FMR protein, which is mutated in Fragile X Syndrome (FXS), also regulates local synaptic translation. Approximately one-third of individuals with FXS are diagnosed with ASD, suggesting synaptic translation defects could contribute to ASD etiology.

En2 transcripts are also observed at low levels in the adult hippocampus. *En2* knock-out studies revealed a decrease in the number of inhibitory GABA interneurons in the CA3 pyramidal layer and stratum lacunosum moleculare of the adult hippocampus. The knock-out mice also display an increase in the susceptibility of kainic acid-induced seizures. These data suggest an imbalance in excitatory/inhibitory (E/I) connectivity, which has been postulated to be a contributing factor to ASD etiology (Tripathi, Sgado et al. 2009).

Post-natally, *En2* is expressed in differentiating and mature granule cells. Studies by Emanuel DiCicco-Bloom's group demonstrated that *En2* functions to promote cell cycle exit and differentiation in developing granule cells (Rossman 2008). The function of *En2* in mature adult granule cells has not been investigated but it is likely to regulate the expression of genes needed for synaptic plasticity and other mature neuronal functions.

In summary although *EN2* was initially selected as a candidate gene based upon similar cerebellar neuroanatomical phenotypes, *En2* coordinates multiple developmental processes. In particular the protein plays an important role in regulating connectivity and neurotransmitter system during CNS development, both of which are relevant to ASD etiology.

5. ENGRAILED 2 genetic analysis

5.1 *rs1861972-rs1861973* association in AGRE and NIMH datasets

Human *EN2* is encoded by two exons in ~8.5kb. In collaboration with Linda Brzustowicz's group at Rutgers University, association analysis was initially performed in 167 Autism Genetic Resource Exchange families (AGRE I dataset- 745 individuals). Positive association with ASD was observed for the common alleles of two intronic SNPs, *rs1861972* and *rs1816973*. Significant association was detected under a narrow (autism) and broad (ASD) diagnosis for both SNPs individually and as a haplotype (A-C *rs1861972-rs1861973*)(Table 2)(Gharani, Benayed et al. 2004). These results were then replicated in two additional datasets (AGREII -222 families, 1102 individuals; NIMH - 129 families, 566 individuals)(Table 2). When all three datasets were combined (518 families, 2413 individuals) more significant results were observed (Table 2)(Benayed, Gharani et al. 2005).

Many factors may contribute to the lack of replication in association studies of complex genetic traits. These include inadequate statistical power, the intrinsic complexity of a disease such as unknown gene-gene and gene-environment interactions as well as locus and allelic heterogeneity in different datasets. Given these limitations, replication of *rs1861972* and *rs1861973* association supports *EN2* as an ASD susceptibility gene.

Risk for the haplotype was then determined. Individual relative risk (RR) estimates the risk the haplotype confers to a given individual, and is calculated by the degree to which the haplotype is over-transmitted from heterozygous parents to affected children. Population

attributable risk (PAR) estimates the risk of the haplotype to the general population and takes into account the degree of over-transmission and frequency of the haplotype. For the 518 families individual RR was estimated as approximately 1.42 and 1.40 under the narrow and broad diagnosis respectively. Because the frequency of the *rs1861972-rs1861973* A-C haplotype is ~67% in the combined sample, this modest individual RR corresponds to a significant PAR of ~39.5% and 38% for the narrow and broad diagnosis of ASD respectively (see Benayed et al 2005 for more details). These data imply that as much as 40% of ASD cases in the population are influenced by the risk allele responsible for *rs1861972* and *rs1861973* association

SNP	Diagnosis	AGRE I (167 families, 750 individuals)	AGRE II (222 families, 1071 individuals)	NIMH (129 families, 515 individuals)	Combined datasets (518 families, 2336 individuals)
		<i>P</i> value	<i>P</i> value	<i>P</i> value	<i>P</i> value
<i>rs1861972</i>	autism	.0106	.0834	.0455	.0010
	ASD	.0050	.0296	.0500	.0002
<i>rs1861973</i>	autism	.0073	.0268	.0234	.00008
	ASD	.0107	.0121	.0181	.000038
A-C haplotype	autism	.0018	.0168	.0321	.0000205
	ASD	.0035	.0061	.0312	.0000088
All haplotypes	autism	.0009	.0048	.0463	.00000065
	ASD	.0024	.0016	.0431	.00000035

Table 2. Summary of *rs1861972* and *rs1861973* association data

5.2 Additional *EN2* association studies

Prior to our association analysis for *EN2*, a case-control study was performed using 100 control and affected individuals from Western/central France. Significant association was observed for a *PvuII* RFLP that we later mapped to ~2.5kb 5' of the promoter (*rs34808376*) (Petit, Herault et al. 1995; Benayed, Gharani et al. 2005). Since our association analysis, 5 separate studies have reported positive results for *rs1861972* or *rs1861973* either individually or as part of a haplotype (Brune, Korvatska et al. 2007; Wang, Jia et al. 2008; Yang, Lung et al. 2008; Sen, Singh et al. 2010; Yang, Shu et al. 2010). These studies were performed in datasets recruited by the authors and represent various ethnicities (Northern/Western European, Chinese, Indian). However differences have also been observed. Additional polymorphisms have been reported to be associated and the allele for *rs1861972* and *rs1861973* that is over-transmitted to affected individuals can vary. These results are summarized in Table 3. These differences could reflect variations in LD blocks for the different ethnicities. It is also possible that different risk alleles exist in various populations.

Study	Ethnicity	n ^a	Associated polymorphisms	ASD associated allele
Petit et al	Western/central French	200	PvuII	CG
Brune et al	Primarily Western/ Northern European	2476	<i>rs1861972</i>	A G
Wang et al	Chinese	630	<i>rs3824068</i>	A
Yang et al (2008)	Chinese	502	<i>rs1861973</i> <i>rs3808331</i>	T G
Yang et al (2010)	Chinese	551	<i>rs1861972</i> <i>rs1861973</i>	A C
Sen et al	Indian	281	<i>rs1861973</i>	C

^a- number of individuals recruited

Table 3. Summary of additional *EN2* association studies

In summary *EN2* association with ASD has been reported by 7 different groups. These data are consistent with *EN2* being an ASD susceptibility gene. However if *EN2* contributes to ASD risk, then we would expect these genetic associations to be due to the co-inheritance of an allele that affects either the regulation or activity of *EN2*. The identification of an associated allele that is also functional would provide additional support for *EN2* being an ASD susceptibility gene.

5.3 *EN2* LD mapping and re-sequencing analysis

The next step in our analysis was to identify candidate common risk alleles by performing linkage disequilibrium (LD) mapping. LD indicates the degree to which alleles in the human population segregate with each other. Two measures for LD are commonly used: D' and r^2 . D' takes into account recombination rate while r^2 includes recombination rate and the frequency of the alleles in the population. For common risk alleles responsible for *rs1861972*-*rs1861973* association, we expected candidates to display the following criteria:

- Candidates must display strong LD (D' and $r^2 > .75$) with *rs1861972* and *rs1861973*
- Candidates must be consistently associated with ASD

LD mapping was then performed for 24 additional polymorphisms that were situated throughout the *EN2* gene (Figure 3). These polymorphisms were typed in the AGRE I dataset and we found that only the intronic SNPs were in significant LD ($D' > 0.72$) with *rs1861972* and *rs1861973*. We then re-sequenced the intron from individuals with ASD that had inherited the A-C haplotype from at least one heterozygous parent. This identified only 1 additional polymorphism (*rs28999108*). *Rs2899108* has a minor allele frequency of 1%, indicating that additional more common polymorphisms are likely not to be identified and *ss38341503* does not fit the criteria of a common risk allele. Association analysis of all intronic SNPs demonstrated that none of them were as consistently or significantly associated as the *rs1861972*-*rs1861973* A-C haplotype (Benayed, Gharani et al. 2005; Benayed, Choi et al. 2009).

However, it was equally possible that *rs1861972* and *rs1861973* was in strong LD with a polymorphisms situated further 5' or 3' of *EN2* that was not tested for association. If this were the case, we would expect these flanking SNPs to be in strong LD with *rs1861972* or *rs1861973* and therefore display r^2 values similar to .767 that is observed between *rs1861972* and *rs1861973*. To identify other polymorphisms that fit these criteria, publicly available




Fig. 3. **Genomic structure of EN2.** The exonic/intronic structure of EN2 is illustrated. The position of 18 polymorphisms tested for association in Benayed et al 2005 is demarcated by arrows below the gene. Numbering refers to the following polymorphisms: 1-*rs6150410*, 2-*PvuII (rs3480837)*, 3-*rs1345514*, 4-*rs3735653*, 5-*rs3735652*, 6-*rs6460013*, 7-*rs7794177*, 8-*rs3824068*, 9-*rs2361688*, 10-*rs3824067*, 11-*rs1861792*, 12-*rs1861973*, 13- *rs28999108*, 14-*rs3808332*, 15-*rs3808331*, 16-*rs4717034*, 17-*rs2361689*, 18-*rs3808329*, 19-*rs1895091*, 20-*rs12533271*, 21-*rs1861958*, 22-*rs3071184*, 23-*rs10259822*, 24-*rs10233570*, 25-*rs11976901*, 26-*rs10243118*. Red labeling denotes ASD association in published studies.

Hapmap data was analyzed. The Hapmap project determined the LD relationship of over 1×10^6 SNPs in four human populations (CEU- Utah residents with ancestry from northern and western Europe; JPT- Tokyo, Japan; CHB- Han Chinese Beijing, China; YRI-Yoruba in Ibadan, Nigeria). r^2 and D' values were first examined for 4 SNPs (*rs1861973*, *rs1861973*, *rs6460013* and *rs1861958*) typed in both the Hapmap and ASD datasets. The values were found to be nearly identical, justifying this approach to identify candidate risk allele. The inter-marker Hapmap r^2 values with *rs1861973* were then determined in all four Hapmap datasets for SNPs within 2 Mb of EN2 (1Mb 5' and 1 Mb 3'). Because 70.3% of the AGRE datasets tested for association were of Northern/Western European descent, the CEU Hapmap data were analyzed first and all SNPs within the 2 Mb region were found to be in weak r^2 with *rs1861973* ($r^2 < .370$). Similar results were observed for the other datasets (Benayed, Choi et al. 2009). These data identified the A-C haplotype as the most appropriate common variant to test for functional differences.

It is also possible that rare variants on the A-C haplotype contribute to ASD risk and the genetic association of the haplotype with ASD. Re-sequencing over 100 individuals did not identify any non-synonymous coding polymorphisms (Benayed, Gharani et al. 2005, Rahman and Millonig, unpublished results). For all these reasons, we decided to focus our research on determining whether the ASD associated A-C haplotype was functional. Our molecular and mouse genetic studies are summarized below and demonstrate that the A-C haplotype functions as a transcriptional activator both *in vitro* and *in vivo*. These data provide molecular genetic support for EN2 being an ASD susceptibility gene.

6. A-C haplotype functional studies

6.1 *In vitro* molecular genetic analysis

To investigate potential function of the ASD associated A-C haplotype, luciferase (luc) assays were conducted. The luc reporter system measures quanta of light, which is a sensitive and reproducible methodology for detecting transcriptional changes. Human EN2 intron was cloned 3' of a basal promoter and luc gene but 5' of the polyA sequence (Figure 4). The construct also included the EN2 splice acceptor and donor sequences. In this way the intron is transcribed and spliced like the endogenous gene. Constructs were generated for both the A-C and G-T haplotypes and are ~8kb in length. The only sequence difference between the constructs is the *rs186972-rs1861973* haplotype.

Both constructs were transfected into primary cultures of cerebellar granule cells. We chose this cell type to test the function of the A-C haplotype for the following reasons. One, cerebellar granule cells are the most abundant neuronal cell type in the brain and because of its small size they can be isolated to near homogeneity. Two, the cells can undergo various steps of development in culture including proliferation, migration, and differentiation. Three, endogenous *En2* is expressed at high levels in cerebellar granule cells.

When we transfected our constructs, the A-C haplotype resulted in significantly higher luc levels compared to the promoter control after 1 day in culture. The G-T haplotype did not display any activity compared to the promoter (Figure 4). Electrophoretic Mobility Shift Assays (EMSAs) were then performed to detect DNA-protein interactions. Granule cell nuclear extract was employed along with a 200bp fragment encompassing either the A-C or G-T haplotypes. A protein complex binds significantly better to the A-C than the G-T haplotype (data not shown). These data demonstrate that the A-C haplotype functions as a transcriptional activator *in vitro*. The A-C haplotype is one of two ASD associated alleles for which function has been ascribed.




Fig. 4. ASD-associated *rs1861972-rs1861973* A-C haplotype increases gene expression. (A) Luciferase (*luc*) constructs used for transfections are diagrammed: TATA - pGL3pro vector driven by SV40 minimal promoter, A-C and G-T - pGL3pro vector containing full-length human *EN2* intron with ASD-associated A-C haplotype (A-C) or unassociated G-T haplotype (G-T). The intron was cloned 3' of *luc* gene and 5' of poly A signal so it is transcribed and spliced as the endogenous gene. (B) Equimolar amount of the three constructs were transiently transfected into P6 mouse cerebellar granule neurons and cultured for 24hrs. Luciferase activities were then measured and normalized to the levels of *Renilla reniformis*. Relative luc units are expressed as percent of TATA control. Note the A-C haplotype significantly increases luc levels. N=4, *P<.05, two tailed paired Student's T test.

6.2 *In vivo* transgenic analysis

Because ASD is a neurodevelopmental disorder, we then generated transgenic mice to determine the developmental cell types and ages in which the A-C haplotype is functional. Our constructs include ~10kb of 5' evolutionarily conserved sequence, the intron, and ~10kb of 3' evolutionarily conserved sequence. Exon 1 of *EN2* was replaced with the Ds-Red fluorescent reporter and exon 2 with the polyadenylation sequence. Like our *luc* constructs, the intron also includes *EN2* splice acceptor and donor sequences so the intron is transcribed and spliced as the endogenous locus. Transgenes for both the A-C and G-T haplotypes were

generated with the only nucleotide difference between the ~25kb transgenes being the *rs186172-rs1861973* haplotype (Figure 5).




Fig. 5. **Transgenic QRTPCR results.** Top) Structure of the A-C and G-T transgenes is illustrated. Exon 1 of *EN2* is replaced with the Ds-Red reporter and exon 2 with the polyA sequence. ~20kb of flanking evolutionarily conserved sequence (green bars) drives expression of Ds-Red. The only difference between the transgenes is the two nucleotides representing the A-C and G-T haplotypes. Bottom) QRTPCR using adult cerebellar RNA was performed for Ds-Red-E5 and *Gapdh* in two pairs of lines with similar copy numbers: A) A-C, line F, 5 copies; G-T, line N, 6.5 copies, B) A-C, line E, 32 copies; G-T, line I, 37 copies. *** $P < .001$ T-test

We have begun our analysis by examining the expression of the transgenes in the adult cerebellum because *En2* is expressed specifically in granule cells. Thus we might expect to observe a similar difference in expression as observed for our *in vitro* luc analysis. Taqman QRTPCR was performed for *Ds-Red* and *Gapdh* on the adult cerebellar RNA isolated from A-C and G-T lines with similar copy numbers. These assays were performed in quadruplicate on three A-C and 3 G-T littermates. The A-C haplotype results in ~250% increase in normalized *Ds-Red* levels compared to the G-T haplotype in the adult cerebellum (Figure 5). These results demonstrate the A-C haplotype functions as a potent activator *in vivo*. These data determined that the ASD A-C haplotype functions as a transcriptional activator both *in vitro* and *in vivo*, providing molecular genetic evidence that *EN2* contributes to ASD risk. We are now examining levels and spatial expression at additional time points (E12.5, E17.5, P6 and adult) relevant to various described functions of *En2* (see Table 1). These studies will determine when, where, and how the A-C haplotype is functional during CNS development, providing the first *in vivo* functional analysis of any common associated allele with ASD.

6.3 Post-mortem and epigenetic analysis

To investigate whether *EN2* levels are also increased in individuals with ASD, post-mortem analysis has been performed. 78 age and sex matched cerebellar samples have been obtained from NICHD Brain and Tissue Bank for Developmental Disorders or Harvard Brain Tissue

Resource Center via Autism Tissue Program (49 control, 29 affected). These samples have been genotyped for *rs1861972* and *rs1861973*, and Taqman QRT-PCR has been performed for *EN2* and *GAPDH*. Normalized *EN2* mRNA levels display a significant increase in affected compared to controls (Figure 6). Further examination of these data suggests that the increase is due to both the *rs1861972-rs1861973* genotype and affection status. A more detailed statistical analysis is ongoing but these results are consistent with *EN2* levels being increased in individuals with ASD. Together our *in vitro*, *in vivo*, and post-mortem studies have demonstrated that increased amounts of *EN2* are consistently associated with ASD, suggesting that elevated levels of the protein alter CNS development to increase risk for ASD.




Fig. 6. **EN2 levels are elevated in ASD individuals.** *EN2* mRNA levels were measured in 29 ASD and 49 control post-mortem cerebellum using Taqman qRT-PCR. *EN2* levels were normalized to *GAPDH* internal controls and average delta Ct values were obtained from triplicates of qPCR. Altered *EN2* levels of ASD individuals are presented as percent of control values. Fold difference was calculated using the formula $2^{-(EN2\Delta Ct - Control\Delta Ct)}$. Error bars indicate standard errors. ** $p < .01$, T-test, two-tailed, unpaired with unequal variance.

The previous data indicate the A-C haplotype results in increased gene expression. However, increased *EN2* levels could also be achieved by epigenetic mechanisms. Environmental factors can affect gene regulation through epigenetic modifications such as differential methylation. Epigenetics likely plays an important role in ASD for the following reasons. One, epigenetics provides an interface between environmental factors and genetic susceptibility. Numerous common environmental factors (e.g. bis-phenol, arsenic, certain antibiotics) affect CpG island methylation and gene expression (Villar-Garea and Esteller 2003). Thus differential environmental exposures could cause variations in epigenetic modifications and gene expression. This model provides a possible explanation for the phenotypic variability observed in ASD and other polygenic disorders (Bjornsson, Fallin et al. 2004; Feinberg 2007). In addition, the methyl-CpG binding proteins, MeCP2 and MBD2, are mutated in Rett Syndrome and ASD, pointing to the importance of epigenetic regulation in ASD (Amir, Van den Veyver et al. 1999; Li, Yamagata et al. 2005; Coutinho, Oliveira et al. 2007; Loat, Curran et al. 2008).

CG dinucleotides are clustered in regions called CpG islands that are regulated by epigenetic mechanisms. CpG dinucleotides are the substrates for cytosine methyl transferases and DNA methylation often leads to decreased expression. Six CpG islands flank human *EN2* with 3 in the gene. Interestingly, a vast majority of these CpG islands are

not observed in mouse or rat, indicating they have evolved since rodent radiation to possibly regulate *EN2* expression. To investigate whether *EN2* is epigenetically regulated, we treated two human neuronal cell lines (Daoy, SH-SY5Y) that express *EN2* with the methylation inhibitor, 5-aza-2'-deoxycytidine (AZA), and a methyl group donor, S-adenosylmethionine (SAM). Preliminary bisulfite sequencing demonstrated methylation of CpGs with SAM treatment while the same dinucleotides are unmethylated in AZA treated cells (Figure 7). Importantly this difference in methylation is correlated with *EN2* mRNA levels. AZA treatment results in increased expression; SAM treatment with decreased levels (Figure 7). Thus, these data are consistent with *EN2* being epigenetically regulated




Fig. 7. *EN2* epigenetic analysis. A and B) Treatment of Daoy and Sh-SY5Y cells with AZA (A) resulted in increased *EN2* mRNA levels (expressed as percent difference relative to untreated). Treatment with SAM (B) resulted in decreased *EN2* mRNA levels (expressed as percent difference relative to untreated). *** $P < .001$ T-test. Bottom) Bisulfite sequencing of PCR products demonstrated the *EN2* promoter is hypomethylated in untreated Daoy cells but methylated upon SAM treatment. An unaffected post-mortem sample is methylated while an affected sample is methylated at the same nucleotides.

We have bisulfite sequenced the promoter in a few post-mortem samples. In affected individuals none of the CpG dinucleotides are methylated while in unaffected individuals the same CpGs were methylated. These CpGs are the same dinucleotides methylated after SAM treatment *in vitro* (Figure 7). In sum, these results are consistent with epigenetic differences contributing to the increase in *EN2* mRNA levels observed in the post-mortem samples. High-throughput epigenetic platform analysis is ongoing to investigate this hypothesis further.

7. Future studies

One important next step is to identify the downstream molecular and cell biological effects of increased *EN2* expression. For this analysis we are generating a humanized *EN2* knock-in




Fig. 8. RMGR humanized *EN2* knock-in. A) Genomic structure of the recombineered BACs is drawn to scale. Human *EN2* G-T haplotype BAC was obtained and recombineered to generate the ASD-associated A-C haplotype. IRES:GFP was then introduced downstream of the *EN2* coding region for the A-C BAC. IRES:Cherry was introduced in the same location for the G-T BAC. Heterotypic loxP (orange triangle) and lox511 (blue triangle) sites were also recombineered into both BACs, ~35kb upstream and downstream of *EN2*. This genomic region does not include any other genes. Empty boxes depict the next flanking genes. The human CpG islands are also illustrated as blue boxes. B) The mouse *En2* locus is illustrated with one small CpG island (blue box). LoxP and lox511 sites have been sequentially targeted onto the same *En2* chromosome. C) The recombineered BACs will then be transfected into our cis loxP-lox511 double-targeted ES cells. Cre recombinase will then be expressed in the ES cells. Since the heterotypic lox sites do not recombine with each other but still recognize both the cre recombinase, the mouse sequence will be replaced with the human locus via cre-mediated recombination through the flanking loxP and lox511 sites. Both A-C and G-T knock-ins will be generated, which will also contain the human CpG islands

mouse whereby we are replacing ~75kb of mouse *En2* with the human sequence. This sequence will also contain the flanking CpG islands. To accomplish this goal we are using a strategy called Recombination Mediated Genome Replacement (RMGR) developed by Andrew Smith PhD (Figure 8)(Wallace, Marques-Kranc et al. 2007). In this way we will be able to determine the molecular and cell biological effects of the A-C haplotype throughout development. Because the human sequence will include the flanking CpG islands, we will also be able to expose the mice to various non-genetic factors that affect epigenetic regulation and investigate how these environmental compounds can either improve or worsen the A-C associated phenotypes.

8. Summary

We have demonstrated that the *EN2* rs1861972-rs1861973 A-C haplotype is significantly associated with ASD in 3 datasets. 6 additional groups have reported *EN2* ASD association, suggesting it is an ASD susceptibility gene. If this possibility is correct, then we would expect the associated alleles to segregate with common or rare variants that functionally alter *EN2* expression or activity. To address this question, we decided to use a combinatorial approach that included human genetics, molecular biology, mouse transgenesis, and human post-mortem analysis. In the three datasets that we studied, LD mapping, re-sequencing, and additional association studies identified the A-C haplotype as the best candidate to test for function. *In vitro* luc assays demonstrated that the A-C haplotype functions as a transcriptional activator, resulting in elevated levels. Importantly transgenic mice have recapitulated these results *in vivo* and will determine when, where, and how the A-C haplotype is functional throughout CNS development. *EN2* levels are also increased in individuals with ASD. Thus elevated amounts of *EN2* seem to be correlated with increased ASD risk. Our preliminary studies indicate that *EN2* is also epigenetically regulated, suggesting exposure to environmental non-genetic factors may also increase *EN2* expression. Future experiments are directed at identifying downstream molecular and cell biological pathways affected by increased *EN2* levels. Finally, *En2* regulates developmental processes implicated in ASD, including the establishment of connectivity maps. In sum, our combinatorial approach has provided evidence that *EN2* is an ASD susceptibility gene.

9. Acknowledgements

We thank NICHD Brain and Tissue Bank for Developmental Disorders, the Harvard Brain Tissue Resource Center for the post-mortem samples, and all participating families for the post-mortem samples. We thank the Autism Tissue Program and especially Jane Pickett for all their help. We acknowledge the funding agencies that have supported this research: NIH (MH076624, MH080429, MH083509), Department of Defense (W81XWH-09-1-0286), NAAR/Autism Speaks, and New Jersey Governor's Council for Medical Research and Treatment of Autism

10. References

- Alarcon, M., R. M. Cantor, et al. (2002). "Evidence for a language quantitative trait locus on chromosome 7q in multiplex autism families." *Am J Hum Genet* 70(1): 60-71.
- Alberi, L., P. Sgado, et al. (2004). "Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons." *Development* 131(13): 3229-3236.

- Amaral, D. G., C. M. Schumann, et al. (2008). "Neuroanatomy of autism." *Trends in neurosciences* 31(3): 137-145.
- Amir, R. E., I. B. Van den Veyver, et al. (1999). "Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2." *Nat Genet* 23(2): 185-188.
- Anderson, G. M. (1987). "Monoamines in autism: an update of neurochemical research on a pervasive developmental disorder." *Medical biology* 65(2-3): 67-74.
- Anderson, G. M., D. X. Freedman, et al. (1987). "Whole blood serotonin in autistic and normal subjects." *J Child Psychol Psychiatry* 28(6): 885-900.
- Auranen, M., R. Vanhala, et al. (2002). "A genomewide screen for autism-spectrum disorders: evidence for a major susceptibility locus on chromosome 3q25-27." *Am J Hum Genet* 71(4): 777-790.
- Baader, S. L., S. Sanlioglu, et al. (1998). "Ectopic overexpression of engrailed-2 in cerebellar Purkinje cells causes restricted cell loss and retarded external germinal layer development at lobule junctions." *J Neurosci* 18(5): 1763-1773.
- Baader, S. L., M. W. Vogel, et al. (1999). "Selective disruption of "late onset" sagittal banding patterns by ectopic expression of engrailed-2 in cerebellar Purkinje cells." *J Neurosci* 19(13): 5370-5379.
- Bauman, M. (1986). "Developmental cerebellar abnormalities: A consistent finding in early infantile autism." *Neurology* 36(1): 190.
- Bauman, M. and T. L. Kemper (1985). "Histoanatomic observations of the brain in early infantile autism." *Neurology* 35(6): 866-874.
- Benayed, R., J. Choi, et al. (2009). "Autism-associated haplotype affects the regulation of the homeobox gene, ENGRAILED 2." *Biol Psychiatry* 66(10): 911-917.
- Benayed, R., N. Gharani, et al. (2005). "Support for the homeobox transcription factor gene ENGRAILED 2 as an autism spectrum disorder susceptibility locus." *Am J Hum Genet* 77(5): 851-868.
- Bjornsson, H. T., M. D. Fallin, et al. (2004). "An integrated epigenetic and genetic approach to common human disease." *Trends Genet* 20(8): 350-358.
- Brune, C. W., E. Korvatska, et al. (2007). "Heterogeneous association between engrailed-2 and autism in the CPEA network." *Am J Med Genet B Neuropsychiatr Genet*.
- Brunet, I., C. Weinl, et al. (2005). "The transcription factor Engrailed-2 guides retinal axons." *Nature* 438(7064): 94-98.
- Campbell, M., E. Friedman, et al. (1975). "Blood serotonin in schizophrenic children. A preliminary study." *International pharmacopsychiatry* 10(4): 213-221.
- Cook, E. H., Jr., R. Rowlett, et al. (1992). "Fluoxetine treatment of children and adults with autistic disorder and mental retardation." *J Am Acad Child Adolesc Psychiatry* 31(4): 739-745.
- Courchesne, E. (1997). "Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism." *Curr Opin Neurobiol* 7(2): 269-278.
- Courchesne, E., R. Yeung-Courchesne, et al. (1988). "Hypoplasia of cerebellar vermal lobules VI and VII in autism." *N Engl J Med* 318(21): 1349-1354.
- Coutinho, A. M., G. Oliveira, et al. (2007). "MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients." *Am J Med Genet B Neuropsychiatr Genet* 144B(4): 475-483.
- Feinberg, A. P. (2007). "Phenotypic plasticity and the epigenetics of human disease." *Nature* 447(7143): 433-440.
- Fox, S. R., Deneris, E.S. (2010). Engrailed is required in the early postnatal period for maintenance of anterior 5-HT neurons. Society for Neuroscience, San Diego, CA.

- Gharani, N., R. Benayed, et al. (2004). "Association of the homeobox transcription factor, ENGRAILED 2, 3, with autism spectrum disorder." *Mol Psychiatry* 9(5): 474-484.
- Gherbassi, D. and H. H. Simon (2006). "The engrailed transcription factors and the mesencephalic dopaminergic neurons." *Journal of neural transmission. Supplementum*(70): 47-55.
- Gordon, C. T., R. C. State, et al. (1993). "A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder." *Archives of general psychiatry* 50(6): 441-447.
- Hanks, M., W. Wurst, et al. (1995). "Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2." *Science* 269(5224): 679-682.
- Herrup, K. and B. Kuemerle (1997). "The compartmentalization of the cerebellum." *Annual review of neuroscience* 20: 61-90.
- Jaynes, J. B. and P. H. O'Farrell (1991). "Active repression of transcription by the engrailed homeodomain protein." *The EMBO journal* 10(6): 1427-1433.
- Joliot, A., A. Maizel, et al. (1998). "Identification of a signal sequence necessary for the unconventional secretion of Engrailed homeoprotein." *Current biology : CB* 8(15): 856-863.
- Joliot, A., A. Trembleau, et al. (1997). "Association of Engrailed homeoproteins with vesicles presenting caveolae-like properties." *Development* 124(10): 1865-1875.
- Joyner, A. L. (1996). "Engrailed, Wnt and Pax genes regulate midbrain--hindbrain development." *Trends Genet* 12(1): 15-20.
- Kuemerle, B., H. Zanjani, et al. (1997). "Pattern deformities and cell loss in Engrailed-2 mutant mice suggest two separate patterning events during cerebellar development." *J Neurosci* 17(20): 7881-7889.
- Lake, C. R., M. G. Ziegler, et al. (1977). "Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism." *Archives of general psychiatry* 34(5): 553-556.
- Lam, K. S., M. G. Aman, et al. (2006). "Neurochemical correlates of autistic disorder: a review of the literature." *Res Dev Disabil* 27(3): 254-289.
- Launay, J. M., C. Bursztein, et al. (1987). "Catecholamines metabolism in infantile autism: a controlled study of 22 autistic children." *Journal of autism and developmental disorders* 17(3): 333-347.
- Leboyer, M., M. P. Bouvard, et al. (1992). "Brief report: a double-blind study of naltrexone in infantile autism." *Journal of autism and developmental disorders* 22(2): 309-319.
- Lesaffre, B., A. Joliot, et al. (2007). "Direct non-cell autonomous Pax6 activity regulates eye development in the zebrafish." *Neural development* 2: 2.
- Leventhal, B. L., E. H. Cook, Jr., et al. (1990). "Relationships of whole blood serotonin and plasma norepinephrine within families." *Journal of autism and developmental disorders* 20(4): 499-511.
- Li, H., T. Yamagata, et al. (2005). "Mutation analysis of methyl-CpG binding protein family genes in autistic patients." *Brain Dev* 27(5): 321-325.
- Lin, L., Sonsalla, P., Matteson, P.G., Silverman, J., Crawley, J.N., Millonig, J.H., DiCiccio-Bloom, E. (2010). Deficiency of Engrailed 2 (En2) Produces Abnormal Development of Forebrain-Projecting, Monoamine Neurotransmitters Systems and Depression Related Behaviors. The 9th International Meeting for Autism research (IMFAR), Philadelphia, PA.
- Liu, J., D. R. Nyholt, et al. (2001). "A genomewide screen for autism susceptibility loci." *Am J Hum Genet* 69(2): 327-340.

- Loat, C. S., S. Curran, et al. (2008). "Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism." *Genes Brain Behav* 7(7): 754-760.
- Logan, C., M. C. Hanks, et al. (1992). "Cloning and sequence comparison of the mouse, human, and chicken engrailed genes reveal potential functional domains and regulatory regions." *Developmental genetics* 13(5): 345-358.
- McBride, P. A., G. M. Anderson, et al. (1989). "Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study." *Archives of general psychiatry* 46(3): 213-221.
- McDougle, C. J., S. T. Naylor, et al. (1996). "Effects of tryptophan depletion in drug-free adults with autistic disorder." *Arch Gen Psychiatry* 53(11): 993-1000.
- McDougle, C. J., S. T. Naylor, et al. (1996). "A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder." *Archives of general psychiatry* 53(11): 1001-1008.
- Millen, K. J., C. C. Hui, et al. (1995). "A role for En-2 and other murine homologues of *Drosophila* segment polarity genes in regulating positional information in the developing cerebellum." *Development* 121(12): 3935-3945.
- Millen, K. J., W. Wurst, et al. (1994). "Abnormal embryonic cerebellar development and patterning of postnatal foliation in two mouse *Engrailed-2* mutants." *Development* 120(3): 695-706.
- Minderaa, R. B., G. M. Anderson, et al. (1994). "Noradrenergic and adrenergic functioning in autism." *Biol Psychiatry* 36(4): 237-241.
- Ohkuma, Y., M. Horikoshi, et al. (1990). "Engrailed, a homeodomain protein, can repress in vitro transcription by competition with the TATA box-binding protein transcription factor IID." *Proceedings of the National Academy of Sciences of the United States of America* 87(6): 2289-2293.
- Peltenburg, L. T. and C. Murre (1997). "Specific residues in the Pbx homeodomain differentially modulate the DNA-binding activity of Hox and *Engrailed* proteins." *Development* 124(5): 1089-1098.
- Petit, E., J. Herault, et al. (1995). "Association study with two markers of a human homeogene in infantile autism." *J Med Genet* 32(4): 269-274.
- Ritvo, E. R., A. Yuwiler, et al. (1970). "Increased blood serotonin and platelets in early infantile autism." *Archives of general psychiatry* 23(6): 566-572.
- Rossmann, I., Lin, L., Kamdar, S., Millonig, J.H., DiCicco-Bloom, E. (2008). The Autism-Associated Gene, *Engrailed 2* (*En2*), Has Age Dependent Effects On Cerebellar Granule Precursor Proliferation And Differentiation When Overexpressed In Vitro. *Proceedings of The 7th International Meeting for Autism research (IMFAR)* London, United Kingdom
- Sen, B., A. S. Singh, et al. (2010). "Family-based studies indicate association of *Engrailed 2* gene with autism in an Indian population." *Genes Brain Behav* 9(2): 248-255.
- Sgado, P., L. Alberi, et al. (2006). "Slow progressive degeneration of nigral dopaminergic neurons in postnatal *Engrailed* mutant mice." *Proceedings of the National Academy of Sciences of the United States of America* 103(41): 15242-15247.
- Sillitoe, R. V., N. Gopal, et al. (2009). "Embryonic origins of *ZebrinII* parasagittal stripes and establishment of topographic Purkinje cell projections." *Neuroscience* 162(3): 574-588.
- Sillitoe, R. V., D. Stephen, et al. (2008). "*Engrailed* homeobox genes determine the organization of Purkinje cell sagittal stripe gene expression in the adult cerebellum." *J Neurosci* 28(47): 12150-12162.

- Sillitoe, R. V., M. W. Vogel, et al. (2010). "Engrailed homeobox genes regulate establishment of the cerebellar afferent circuit map." *The Journal of neuroscience : the official journal of the Society for Neuroscience* 30(30): 10015-10024.
- Simon, H. H., H. Saueressig, et al. (2001). "Fate of midbrain dopaminergic neurons controlled by the engrailed genes." *The Journal of neuroscience : the official journal of the Society for Neuroscience* 21(9): 3126-3134.
- Simon, H. H., C. Scholz, et al. (2005). "Engrailed genes control developmental fate of serotonergic and noradrenergic neurons in mid- and hindbrain in a gene dose-dependent manner." *Mol Cell Neurosci* 28(1): 96-105.
- Simon, H. H., S. Thuret, et al. (2004). "Midbrain dopaminergic neurons: control of their cell fate by the engrailed transcription factors." *Cell and tissue research* 318(1): 53-61.
- Sugiyama, S., A. A. Di Nardo, et al. (2008). "Experience-dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity." *Cell* 134(3): 508-520.
- Takahashi, S., H. Kanai, et al. (1976). "Reassessment of elevated serotonin levels in blood platelets in early infantile autism." *Journal of autism and childhood schizophrenia* 6(4): 317-326.
- Tolkunova, E. N., M. Fujioka, et al. (1998). "Two distinct types of repression domain in engrailed: one interacts with the groucho corepressor and is preferentially active on integrated target genes." *Molecular and cellular biology* 18(5): 2804-2814.
- Tripathi, P. P., P. Sgado, et al. (2009). "Increased susceptibility to kainic acid-induced seizures in Engrailed-2 knockout mice." *Neuroscience* 159(2): 842-849.
- van Dijk, M. A. and C. Murre (1994). "extradenticle raises the DNA binding specificity of homeotic selector gene products." *Cell* 78(4): 617-624.
- Villar-Garea, A. and M. Esteller (2003). "DNA demethylating agents and chromatin-remodelling drugs: which, how and why?" *Curr Drug Metab* 4(1): 11-31.
- Wallace, H. A., F. Marques-Kranc, et al. (2007). "Manipulating the mouse genome to engineer precise functional syntenic replacements with human sequence." *Cell* 128(1): 197-209.
- Wang, L., M. Jia, et al. (2008). "Association of the ENGRAILED 2 (EN2) gene with autism in Chinese Han population." *American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 147B(4): 434-438.
- Wizenmann, A., I. Brunet, et al. (2009). "Extracellular Engrailed participates in the topographic guidance of retinal axons in vivo." *Neuron* 64(3): 355-366.
- Wurst, W., A. B. Auerbach, et al. (1994). "Multiple developmental defects in Engrailed-1 mutant mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum." *Development* 120(7): 2065-2075.
- Yang, P., F. W. Lung, et al. (2008). "Association of the homeobox transcription factor gene ENGRAILED 2 with autistic disorder in Chinese children." *Neuropsychobiology* 57(1-2): 3-8.
- Yang, P., B. C. Shu, et al. (2010). "Intronic single nucleotide polymorphisms of engrailed homeobox 2 modulate the disease vulnerability of autism in a han chinese population." *Neuropsychobiology* 62(2): 104-115.
- Zec, N., D. H. Rowitch, et al. (1997). "Expression of the homeobox-containing genes EN1 and EN2 in human fetal midgestational medulla and cerebellum." *J Neuropathol Exp Neurol* 56(3): 236-242.



Autism Spectrum Disorders - From Genes to Environment

Edited by Prof. Tim Williams

ISBN 978-953-307-558-7

Hard cover, 400 pages

Publisher InTech

Published online 06, September, 2011

Published in print edition September, 2011

Autism spectrum disorders are a major topic for research. The causes are now thought to be largely genetic although the genes involved are only slowly being traced. The effects of ASD are often devastating and families and schools have to adapt to provide the best for people with ASD to attain their potential. This book describes some of the interventions and modifications that can benefit people with ASD.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Jiyeon Choi, Silky Kamdar, Taslima Rahman, Paul G Matteson and James H Millonig (2011). ENGRAILED 2 (EN2) Genetic and Functional Analysis, Autism Spectrum Disorders - From Genes to Environment, Prof. Tim Williams (Ed.), ISBN: 978-953-307-558-7, InTech, Available from: <http://www.intechopen.com/books/autism-spectrum-disorders-from-genes-to-environment/engrailed-2-en2-genetic-and-functional-analysis>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](#), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen